Status:
COMPLETED
Effect of Montelukast Versus Co Enzyme in Sepsis
Lead Sponsor:
Ain Shams University
Conditions:
Sepsis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
Sepsis is a leading cause of morbidity and mortality in intensive care units. Sepsis is a life-threatening organ dysfunction linked to a dysregulated host response to infection. It leads to overwhelmi...
Detailed Description
Sepsis is now defined as a life-threatening organ dysfunction linked to a dysregulated host response to infection. This organ dysfunction can be identified using the Sequential Organ Failure Assessmen...
Eligibility Criteria
Inclusion
- Age \>18 years old.
- Males and females
- Confirmed diagnosis of sepsis according to the third sepsis definition which include documented or suspected infection, plus an acute change in total SOFA score ≥ 2 points
Exclusion
- Pregnancy
- A severe moribund state
- An anticipated ICU stay of less than 24 hours.
- Patients with a history of hypersensitivity to montelukast or co enzyme Q10.
- Patients with systemic eosinophilia in the blood or vasculitis.
- Patients with neuropsychiatric diseases as hallucinations, depression or suicidal thoughts that put the patient at risk when participating in the study.
- Unable to receive enteral medications.
Key Trial Info
Start Date :
February 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2023
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT05293132
Start Date
February 1 2022
End Date
June 1 2023
Last Update
July 20 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ghada El Adly
Cairo, Egypt, 112311